Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

globenewswire.com - 2026-07-10 08:35:00

The U.S. Food ​and Drug ‌Administration said on Friday ​it has ​approved Sanofi's blood ⁠cancer drug, ​Sarclisa, which ​can be given under the ​skin through ​a wearable injector, ‌offering ⁠multiple myeloma patients a less burdensome ​alternative ​to ⁠intravenous infusions.

reuters.com - 2026-07-10 08:22:07

The European Commission said on Wednesday ​it would seek feedback ‌on commitments offered by French pharmaceutical company Sanofi to ​address concerns that ​it may have breached competition ⁠rules in a ​flu vaccine marketing campaign.

reuters.com - 2026-07-08 06:00:54

Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.

zacks.com - 2026-07-01 10:26:09

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

globenewswire.com - 2026-07-01 01:30:00

When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive dividend income.

fool.com - 2026-06-30 15:04:19

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

fool.com - 2026-06-30 07:45:03

The European Commission opened on Friday an ​investigation into whether French ‌drug giant Sanofi breached EU competition rules in a flu ​vaccine marketing campaign.

reuters.com - 2026-06-26 05:46:56

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

fool.com - 2026-06-25 09:53:00

Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing lifecycle management to mitigate 2031 U.S. LOE risk. Dupixent concentration is not unique. Management continues to pursue lifecycle management initiatives, including new formulations and a hyaluronidase co-formulation, while planning conservatively under a no-extension scenario.

seekingalpha.com - 2026-06-25 07:18:10

Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases.

globenewswire.com - 2026-06-25 02:00:00

Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.

zacks.com - 2026-06-23 12:26:11

The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.

wsj.com - 2026-06-23 01:37:00

Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.

globenewswire.com - 2026-06-23 01:15:00

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

zacks.com - 2026-06-22 10:36:15

Sanofi a ppoints  Paulo Fontoura   as   Global  Head of  R&D Paris ,  June 22 ,   2026. Sanofi today announced the appointment of Paulo F o ntoura ,  MD, PhD, FAAN,   as  Executi v e Vice President, Global  Head of Research & Development  Pharma, effective September 1, 2026.

globenewswire.com - 2026-06-22 02:00:00

Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IV Second global approval for Sarclisa SC following the EU Paris, June 19, 2026. The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma (MM).

globenewswire.com - 2026-06-19 06:31:00

Sanofi remains a compelling investment opportunity, driven by a robust pipeline and strong fundamentals. Sarclisa sales in Q1 of 2026 grew by 30.1% to $193.21 million; expansion with on-body injector [OBI] could make a push to compete in the MM space against Darzalex. Dupixent sales in Q1 of 2026 grew by 30.8% to $4.85 billion, boosted by continued strong execution and expansion for pediatric patients in CSU.

seekingalpha.com - 2026-06-15 16:49:17

SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.

zacks.com - 2026-06-15 13:15:29

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

globenewswire.com - 2026-06-15 12:05:00

The U.S. ​Food and ‌Drug Administration approved ​Sanofi's ​injection to slow ⁠the loss ​of ​the body's own insulin production ​in ​children aged 8 ‌to ⁠17 years recently diagnosed ​with ​stage ⁠3 type ​1 ​diabetes, ⁠the agency said ⁠on ​Friday.

reuters.com - 2026-06-12 17:19:26

New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time. New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time.

globenewswire.com - 2026-06-12 08:22:00

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

investors.com - 2026-06-10 10:15:51

SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.

zacks.com - 2026-06-10 10:07:09

Biopharmaceutical company Sanofi will stop a Phase ​3 trial of its drug ‌riliprubart for a rare neurological condition after an interim ​analysis of the ​study found it unlikely to ⁠provide sufficient efficacy.

reuters.com - 2026-06-10 02:38:42

The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.

wsj.com - 2026-06-10 02:28:00

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 .  Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.

globenewswire.com - 2026-06-10 01:00:00

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the first participant has been dosed in the first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971), an oral, potent and selective IRAK4 degrader, in adult healthy volunteers and hidradenitis suppurativa (HS) patients.

globenewswire.com - 2026-06-09 07:00:00

SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.

zacks.com - 2026-06-08 13:41:09

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin's AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The co.

businesswire.com - 2026-06-05 07:00:00

Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.

zacks.com - 2026-06-04 10:10:26

Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.

globenewswire.com - 2026-06-04 04:07:00

SAN FRANCISCO--(BUSINESS WIRE)-- #SnowflakeSummit--SNOWFLAKE SUMMIT 26 – Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced at Snowflake Summit 26 that Sanofi, one of the world's leading biopharmaceutical companies, has established a new blueprint for AI-powered biopharma with its launch of "Concierge for Field," a new AI agent built with Snowflake Cortex AI that prepares Sanofi's global sales representatives for every physician or provider visit. In a single conversation, a rep can ask for a pre-.

businesswire.com - 2026-06-02 09:08:00

Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.

zacks.com - 2026-05-29 11:01:14

Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.

globenewswire.com - 2026-05-28 01:00:00

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.

zacks.com - 2026-05-22 13:15:26

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

globenewswire.com - 2026-05-19 12:37:00

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

zacks.com - 2026-05-19 12:26:24

French drugmaker Sanofi said on Monday ‌a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.

reuters.com - 2026-05-18 15:36:03

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

globenewswire.com - 2026-05-18 15:30:00

I highlight five dividend stocks—HTO, ES, SNY, NLY, and AMCR—trading below fair value, each with strong balance sheets and good potential growth prospects. Each stock is projected to deliver double-digit average annual total returns (11.6%–20%) through 2030, with yields averaging nearly 7%. Scenario modeling incorporates expected EPS growth, dividend growth, and target P/E multiples, supporting robust total return forecasts even in recessionary or inflationary environments.

seekingalpha.com - 2026-05-16 22:58:00

The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.

fool.com - 2026-05-13 13:15:00

Sanofi (SNY) is rated a Strong BUY, with a robust pipeline, strong FCF, and a compelling turnaround under new leadership. SNY offers a 5.5%+ dividend yield, undervalued multiples, and projected 16–20% annualized total returns over the next five years. Recent product launches drove 14% of Q1 revenue, with 80 pipeline products and 23 in mid-to-late stage development supporting future growth.

seekingalpha.com - 2026-05-11 11:08:22

Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.

zacks.com - 2026-05-08 13:41:31

Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review program, STAT ​News reported on Wednesday.

reuters.com - 2026-05-06 14:38:21

The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation, today announced Sanofi as one of its inaugural industry sponsors.

prnewswire.com - 2026-05-06 12:42:00

A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.

fool.com - 2026-04-30 04:44:00

Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa.

globenewswire.com - 2026-04-29 12:00:00

Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing performance, continue to make good on their commitments to return more capital to shareholders.

marketbeat.com - 2026-04-28 13:25:59

Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.

fool.com - 2026-04-25 01:30:00